Compare Stanley Black & Decker, Inc. (SWK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs 10X Genomics Inc — how do they compare? Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Stanley Black & Decker, Inc. is far larger — about 2.5× 10X Genomics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SWK | TXG | |
|---|---|---|
Market Cap | $13.60B | $5.48B |
52-Week High | $94.12 | $45.80 |
52-Week Low | $62.12 | $11.34 |
Enterprise Value | $19.77B | $5.02B |
Dividend Yield | 3.79% | — |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $88.19, down 2.2% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.59 estimate. Fundamentals reveal a P/E of 35.86 and net income margin of 2.44%, while cash flow trends indicate stable operations. Recent news highlights strength in aerospace and automotive segments but notes weak Tools & Outdoor demand.
SWK offers value with a P/S of 0.87 and dividend yield appeal, but high debt and margin pressures pose risks. The consensus price target is $83.00, with 43% of analysts rating it a buy. Earnings growth and debt reduction are key catalysts, though sector headwinds and economic sensitivity remain concerns for investors.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
